Compass Therapeutics
CMPXPhase 3Compass Therapeutics is advancing a robust portfolio of therapeutic candidates designed to optimize critical components required for an effective anti-tumor response. The company's platforms enable rapid identification of diverse therapeutic leads, with a strategic focus on the tumor microenvironment. Compass is publicly traded (NASDAQ: CMPX) and is progressing its lead candidates through clinical development to create transformative cancer therapies.
CMPX · Stock Price
Historical price data
AI Company Overview
Compass Therapeutics is advancing a robust portfolio of therapeutic candidates designed to optimize critical components required for an effective anti-tumor response. The company's platforms enable rapid identification of diverse therapeutic leads, with a strategic focus on the tumor microenvironment. Compass is publicly traded (NASDAQ: CMPX) and is progressing its lead candidates through clinical development to create transformative cancer therapies.
Technology Platform
Proprietary platforms enabling rapid identification and optimization of therapeutic antibody candidates with focus on the tumor microenvironment and bridging innate and adaptive immune responses.
Pipeline
7| Drug | Indication | Stage | Watch |
|---|---|---|---|
| CTX-009 + Paclitaxel | Biliary Tract Cancer | Phase 2/3 | |
| CTX-009 | Metastatic Colorectal Cancer | Phase 2 | |
| CTX-009 + CTX-471 | Glioblastoma | Phase 1/2 | |
| Gemcitabine + Cisplatin + Durvalumab + CTX-009 | Metastatic Biliary Tract Cancer | Phase 1/2 | |
| CTX-009 (ABL001) + Paclitaxel + Irinotecan | P1b: Advanced Solid Tumors | Phase 1/2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Competes in the crowded oncology immunotherapy space against large pharmaceutical companies and numerous biotechs. Differentiation comes from proprietary discovery platforms and focus on tumor microenvironment. Success requires demonstrating clinical advantages over existing checkpoint inhibitors and other immunomodulators.